Anti-CD20 Monoclonal Antibodies Market

Anti-CD20 monoclonal antibody is an anti-tumor agent for the treatment of non-hodge B cell malignancy.Unlike conventional treatments, these antibodies attack the CD20 antigen on cancer cells.
Anti-CD20 Monoclonal Antibodies Market contains market size and forecasts of Anti-CD20 Monoclonal Antibodies in global, including the following market information:
Global Anti-CD20 Monoclonal Antibodies Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Anti-CD20 Monoclonal Antibodies Market Sales, 2017-2022, 2023-2028, (KG)
Global top five Anti-CD20 Monoclonal Antibodies companies in 2021 (%)
The global Anti-CD20 Monoclonal Antibodies market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
First Generation Anti-CD20 Monoclonal Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Anti-CD20 Monoclonal Antibodies include Genmab, Amgen, Celltrion, Roche, Novartis AG, Pfizer, Biogen, Genentech and Immunomedics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Anti-CD20 Monoclonal Antibodies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Anti-CD20 Monoclonal Antibodies Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (KG)
Global Anti-CD20 Monoclonal Antibodies Market Segment Percentages, by Type, 2021 (%)
First Generation Anti-CD20 Monoclonal Antibody
Second Generation Anti-CD20 Monoclonal Antibody
Third Generation Anti-CD20 Monoclonal Antibody
Global Anti-CD20 Monoclonal Antibodies Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (KG)
Global Anti-CD20 Monoclonal Antibodies Market Segment Percentages, by Application, 2021 (%)
Oncology
Neurology
Immunology
Global Anti-CD20 Monoclonal Antibodies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (KG)
Global Anti-CD20 Monoclonal Antibodies Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Anti-CD20 Monoclonal Antibodies revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Anti-CD20 Monoclonal Antibodies revenues share in global market, 2021 (%)
Key companies Anti-CD20 Monoclonal Antibodies sales in global market, 2017-2022 (Estimated), (KG)
Key companies Anti-CD20 Monoclonal Antibodies sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Genmab
Amgen
Celltrion
Roche
Novartis AG
Pfizer
Biogen
Genentech
Immunomedics
Spectrum Pharmaceuticals
Bio-Rad Laboratories
LFB Biotechnologie